Founded in January 2013, Vigonvita Life Sciences Co., Ltd. (“Vigonvita”) is an innovation-driven biopharmaceutical company dedicated to meeting clinical needs in the treatment of neuropsychiatric, infectious and andrological diseases. Vigonvita has a complete innovative drug R&D system in Suzhou and Shanghai, undertaking all stages of the work including the drug discovery, druggability assessment, identification of candidate compounds, preclinical research, clinical research and the market launch of the innovative drug.
Vigonvita now has a competitive product pipeline. MINDVY?(VV116) was approved in Uzbekistan on December 28, 2021, for the treatment of mild, moderate, and severe COVID-19 infections in adults. 民得維?(VV116) received conditional approval for marketing from the Chinese NMPA on January 2023，and was converted from conditional to regular approval in January 2025 for the treatment of mild-to-moderate SARS-CoV-2 infection in adult patients. The Phase I clinical study of VV116 for the treatment of Respiratory Syncytial Virus (RSV) infection has been completed, and the Phase II clinical trial is currently in progress. ONVITA? (TPN171) was approved for marketing in Uzbekistan on September 20, 2022 for the treatment of erectile dysfunction (ED). The ED indication of TPN171 has completed Phase III clinical studies in China, and its new drug application (NDA) has been accepted by the NMPA; its pulmonary arterial hypertension indication is in the Phase II clinical stage in China.
The pharmaceutical manufacturing subsidiary, Vigonvita (Lianyungang) Pharmaceutical Co., Ltd is located in Lianyungang National Development Zone, China Pharmaceutical Port, covering an area of 33 acres. It has an API and formulation production system that meets domestic and international GMP standards and EHS (environmental, health, and safety) requirements. This includes a multi-functional and modular emergency production platform, which has the emergency response capability to quickly transform production technology, adjust the layout of production lines and start production in emergency situations.
Vigonvita has applied for more than 110 invention patents and now has 54 granted invention patents. We have undertaken a number of national and provincial fund projects. We have been honored as “National High-tech Enterprise”, “Suzhou Gusu Innovative Leading Talent”, “Suzhou Industrial Park Innovative Leading Talent” enterprise, “Jiangsu Province Science and Technology SME” and so on.
Vigonvita will continue to uphold the concept of innovation-driven development, and deepen its efforts in the treatment of neuropsychiatric, infectious and andrological diseases, so as to relieve patients’ pains and make contributions to the society.
Headquarters of in Suzhou, with R&D centers set up in Suzhou?and Shanghai. Established an API and formulation manufacturing plant in Lianyungang, Jiangsu Province, to build a pharmaceutical manufacturing system that meets GMP standards and EHS (environment, health and safety) requirements. This includes a multi-functional and modular emergency production platform, which has the emergency response capability to quickly transform production technology, adjust the layout of production lines and start production in emergency situations. Vigonvita Tashkant was established in Uzbekistan, tasked with the registration and sales of the products in Uzbekistan. Currently, three products have been approved for marketing in Uzbekistan. Based on this, Vigonvita is further expanding its business in other countries such as North Africa, Central Asia, the Middle East, and Russia.
Guanghui Tian
Co-founderPhD, Shanghai Institute of Materia?Medica, Chinese Academy of Sciences
Industrial Professor, Pharmacy department, Suzhou University
Suzhou “key industry urgently-needed talents”
As the leader or participated in a number of national scientific research projects, such as Major Science and Technology Special Project for “Significant New Drugs Development” (“重大新藥創(chuàng)制”科技重大專項) and the National High-tech R&D Program (“863 Program”).
Zhiqiang Wang
Deputy General Manager
PhD, Chinese?Pharmaceutical University
Suzhou “Gusu Innovative?Leading Talents”
More than 20 years of experience in R&D, clinical trial?and registration of innovative drugs
Hosted and participated in 6?national?major?projects such as?“863?Program” and “Innovative?Drug Creation?”
Awarded “Second Prize of of China Pharmaceutical Society?Science and Technology Award”, “First Prize of Shanghai Pharmaceutical Science and Technology Award”, “Third Prize of Jiangsu Scientific and Technological Progress” and other honors
Tianwen Hu
Deputy General Manager
PhD, Xinjiang Technical Institute of Physics and Chemistry , Chinese Academy of Sciences
Years of experience in innovative drug development,has published more than 20 Science Citation Index (SCI) research papers.
and participated in a number of provincial science and technology projects as project leaders or core members.
Played an important role in the development of the anti-new coronavirus drug VV116
2022 National Key R&D Program?——?Clinical Study of VV116, a New Oral Anti-New Coronavirus Drug, in “BRI” Countries
2021 Special project of the Ministry of Industry and Information Technology?——?rapid discovery software and compound library for specific antiviral innovative drugs, led by Huawei, to build a cloud platform for compound discovery, registration, clinical trial and industrialization.
2021 National Key Research and Development Program?——?Clinical Study of VV116, a New Oral Nucleoside Anti-New Coronavirus Drug Candidate
2019 The State Scientific and Technological Major Project “Creation of Key?Innovative?Drug”?——?Registration and Marketing of Anti-Hepatitis C Drug Sofosbuvir in Central Asia
2019 “BRI” International Union of Scientific Organizations Anti-epidemic Special Project?——?China-Uzbekistan?Joint Anti-New Coronavirus Infection Emergency Drug Research and Development
2018 National “Creation of Key?Innovative?Drugs” Scientific and Technological Major Program?——?Research and Development of New Small Molecule Drugs with New Targets and Their Key Innovative Technology System
2022 Special Funds for Science and Technology Programs in Jiangsu Province (Key R&D Program for Social Development)?——?Phase I Clinical Study of VV116, an Emergency Drug Against New Coronavirus Infections
2021 Suzhou Technology Transfer System Construction Project??—— Anti-Epileptic Class 1 Innovative?Drug TPN102
2020 Suzhou Technology Transfer System Construction Project??—— R&D and industrialization of TPN171, a new anti-pulmonary arterial hypertension class 1?drug
2019 Jiangsu Province Industry-University-Research Collaboration Program??—— Clinical Study of TPN171, a New Class 1 Drug against Pulmonary Arterial Hypertension
2019 Jiangsu Province Policy Guidance Program (International Science and Technology Cooperation)?—— Collaborative Development and Overseas Application Demonstration of Innovative?and Special Drugs in Central Asia
2017 Passed ISO9001:2015-Quality Management System Certification
2024 Passed ISO14001:2015-Environmental Management System Certification
2024 Passed ISO45001:2018-Occupational Health and Safety Management System Certification
